Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Atorvastatin · DIN 02295296 Manufacturer: Apotex Inc.; listing date 2010-06-18 Health Canada: Marketed since 2010-05-19 · brand APO-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 40 MG · company Apotex inc · schedule Prescription

DIN 02295296: Apo-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600037; group id 296; item number 0648; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2342; ministry $0.2342 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295296 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78060

Interchangeable products

AG-Atorvastatin · DIN 02478161 · $0.2342 Ach-Atorvastatin Calcium · DIN 02457776 · $0.2342 Atorvastatin · DIN 02348721 · $0.2342 Atorvastatin · DIN 02475049 · $0.2342 Atorvastatin · DIN 02545489 · $0.2342 Atorvastatin-40 · DIN 02411377 · $0.2342 Auro-Atorvastatin · DIN 02407272 · $0.2342 Bio-Atorvastatin · DIN 02481200 · $0.2342 Jamp Atorvastatin Calcium · DIN 02504219 · $0.2342 Jamp-Atorvastatin · DIN 02391074 · $0.2342 Lipitor · DIN 02230714 · $0.2342 M-Atorvastatin · DIN 02471183 · $0.2342 Mar-Atorvastatin · DIN 02454033 · $0.2342 Mint-Atorvastatin · DIN 02479524 · $0.2342 Mylan-Atorvastatin · DIN 02392968 · $0.2342 NRA-Atorvastatin · DIN 02476533 · $0.2342 PMS-Atorvastatin · DIN 02477165 · $0.2342 PMSC-Atorvastatin · DIN 02507250 · $0.2342 PRZ-Atorvastatin · DIN 02521571 · $0.2342 Ratio-Atorvastatin · DIN 02350327 · $0.2342 Reddy-Atorvastatin · DIN 02417952 · $0.2342 Sandoz Atorvastatin · DIN 02324962 · $0.2342 Taro-Atorvastatin · DIN 02313723 · $0.2342 Teva-Atorvastatin · DIN 02310910 · $0.2342

Shortage status: resolved shortage (ended 2024-06-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295296

Shortage record checked 2026-09-13T08:10:21.292534+00:00